News | February 05, 2025
Pfizer reports 2024 revenues 7% higher at $63.6 billion
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
Enzalutamide Tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
Study achieves primary endpoint of radiographic progression-free survival
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
Subscribe To Our Newsletter & Stay Updated
